Supplementary material

Supplementary Table 1. Associations of demographic and clinical characteristics with sexual functioning.

| Variables | Pre-radiotherapy(n = 54) | Post-radiotherapy(n = 20) |
| --- | --- | --- |
| n | FSFI total scores | *p* | n | FSFI total scores | *p* |
| Age in years, *p* | 54 | 0.17 | 0.232 | 20 | 0.11 | 0.650 |
| Race |
|  | Black/African American | 26 | 9.3 (5.1–24.5) | 0.075 | 7 | 14.7 (9.2–34.2) | 0.337 |
| White | 19 | 5.2 (4.4–7.3) | 8 | 10.3 (5.2–15.5) |
| Other | 9 | 4.2 (2.8–12.8) | 5 | 17.6 (1.01–25.4) |
| Marital status |
|  | Married/domestic partnership | 28 | 5.6 (3.8–13.6) | 0.461 | 13 | 16.4 (10.3–20.0) | 0.241a |
| Other | 26 | 7.1 (4.4–26.5) | 7 | 9.2 (4.2–30.0) |
| Cancer type |
|  | Cervical | 24 | 4.9 (2.2–7.3) | 0.002 | 8 | 11.2 (6.2–16.4) | 0.270a |
| Endometrial | 30 | 12.3 (5.1–27.5) | 12 | 17.0 (6.3–27.9) |
| FIGO cancer stage |
|  | Ⅰ | 28 | 6.7 (4.4–22.4) | 0.650 | 11 | 12.8 (9.2–19.2) | 0.633 |
| Ⅱ | 15 | 5.6 (4.4–18.3) | 6 | 15.9 (9.3–24.1) |
| Ⅲ | 11 | 5.2 (2.6–7.3) | 3 | 5.2 (3.6–30.0) |
| Prior treatment history |
|  | None | 22 | 5.2 (2.0–9.0) | 0.039 | 6 | 12.1 (4.8–17.9) | 0.444a |
| Chemotherapy | 8 | 5.4 (3.8–25.6) | 0.971a | 4 | 20.4 (6.6–33.2) | 0.437a |
| Surgery | 31 | 7.3 (4.7–19.8) | 0.095 | 13 | 12.8 (7.2–20.4) | 0.877a |
| Radiotherapy |
|  | External beam radiation therapy |  |  |  | 14 | 10.3 (5.2–17.9) | 0.207a |
| Vaginal brachytherapy |  |  |  | 17 | 12.8 (7.2–18.4) | 0.305a |
| FACT-G PWB scores, *p* | 52 | 0.47 | 0.001 | 20 | 0.04 | 0.869 |
| FACT-G EWB scores, *p* | 52 | 0.11 | 0.422 | 20 | −0.16 | 0.504 |

Data are presented as median (interquartile range) unless otherwise noted and analyzed using Spearman correlation analysis (for age), Mann-Whitney U tests, or Kruskal-Wallis tests. aExact tests. RT, radiotherapy; FSFI, the Female Sexual Function Index; FACT-G, the Functional Assessment of Cancer Therapy-General; PWB, physical well-being; EWB, emotional well-being; FIGO, the International Federation of Gynecology and Obstetrics.